The place of antispasmodic drugs in modern therapy of irritable bowel syndrome
https://doi.org/10.21518/ms2023-127
Abstract
Irritable bowel syndrome (IBS) is a common functional disease of the gastrointestinal tract, affecting a large number of adults worldwide, and leads to a significant decrease in the quality of life. IBS places a heavy burden on patients, most of whom are able-bodied population, as well as doctors and the healthcare system. The pathogenesis of this disease is multifactorial and includes the brain-intestine axis, disorders of the immune function of the mucous membrane, visceral hypersensitivity, changes in the motility of the gastrointestinal tract, changes in the microbial composition of the intestine. Based on the fact that changes in intestinal motility and visceral hypersensitivity are among the key factors in the pathogenesis of the disease, he use of antispasmodic drugs as part of complex therapy is justified. Mebeverin is a myotropic antispasmodic drug recommended for use in patients with IBS according to Rome IV Criteria, as well as clinical recommendations of the Russian Gastroenterological Association and the Association of Coloproctologists of Russia. According to available data, mebeverin has proven to be an effective and safe antispasmodic used to treat patients with IBS. The article presents a clinical case demonstrating the experience of effective use of the drug Mebespalin®. A patient with a diagnosis of IBS with a predominance of constipation is recommended to take an antispasmodic, as well as lifestyle modification – the addition of fiber-rich foods, sufficient drinking regime and increased physical activity. A week after the start of treatment, the patient noted an improvement in her condition – abdominal pain did not bother, the stool normalized.
About the Authors
K. N. Khalaidzheva
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Kseniya N. Khalaidzheva, Postgraduate Student of the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases
8, Bldg. 2, Trubetskaya St., Moscow, 119991
V. N. Drozdov
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Vladimir N. Drozdov, Dr. Sci. (Med.), Professor of the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases
8, Bldg. 2, Trubetskaya St., Moscow, 119991
E. V. Shikh
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Evgenia V. Shikh, Dr. Sci. (Med.), Professor, Head of the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases
8, Bldg. 2, Trubetskaya St., Moscow, 119991
S. Yu. Serebrova
Scientific Centre for Expert Evaluation of Medicinal Products;
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Svetlana Yu. Serebrova, Dr. Sci. (Med.), Chief Researcher; Professor of the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases
8, Bldg. 2, Petrovsky Boulevard, Moscow, 127051;
8, Bldg. 2, Trubetskaya St., Moscow, 119991
References
1. Lacy B.E., Mearin F., Chang L., Chey W.D., Lembo A.J., Simren M. Spiller R. Bowel Disorders. Gastroenterology. 2016;150(6)1393–1407.E5. https://doi.org/10.1053/j.gastro.2016.02.031.
2. Canavan C., West J., Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther. 2014;40(9):1023–1034. https://doi.org/10.1111/apt.12938.
3. Lovell R.M., Ford A.C. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712–721.e4. https://doi.org/10.1016/j.cgh.2012.02.029.
4. Singh P., Staller K., Barshop K., Dai E., Newman J., Yoon S. et al. Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation. World J Gastroenterol. 2015;21(26):8103–8109. https://doi.org/10.3748/wjg.v21.i26.8103.
5. Fond G., Loundou A., Hamdani N., Boukouaci W., Dargel A., Oliveira J. et al. Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2014;264(8):651–660. https://doi.org/10.1007/s00406-014-0502-z.
6. Casiday R.E., Hungin A.P., Cornford C.S., de Wit N.J., Blell M.T. GPs’ explanatory models for irritable bowel syndrome: a mismatch with patient models? Fam Pract. 2009;26(1):34–39. https://doi.org/10.1093/fampra/cmn088.
7. Drossman D.A. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016;150(6):1262–1279.E2. https://doi.org/10.1053/j.gastro.2016.02.032.
8. Simrén M., Barbara G., Flint H.J., Spiegel B.M., Spiller R.C., Vanner S. et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013;62(1):159–176. https://doi.org/10.1136/gutjnl-2012-302167.
9. Rajilić-Stojanović M., Jonkers D.M., Salonen A., Hanevik K., Raes J., Jalanka J. et al. Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena? Am J Gastroenterol. 2015;110(2):278–287. https://doi.org/10.1038/ajg.2014.427.
10. Pittayanon R., Lau J.T., Yuan Y., Leontiadis G.I., Tse F., Surette M., Moayyedi P. Gut Microbiota in Patients With Irritable Bowel Syndrome-A Systematic Review. Gastroenterology. 2019;157(1):97–108. https://doi.org/10.1053/j.gastro.2019.03.049.
11. Hugerth L.W., Andreasson A., Talley N.J., Forsberg A.M., Kjellström L., Schmidt P.T. et al. No distinct microbiome signature of irritable bowel syndrome found in a Swedish random population. Gut. 2020;69(6):1076–1084. https://doi.org/10.1136/gutjnl-2019-318717.
12. Adak A., Khan M.R. An insight into gut microbiota and its functionalities. Cell Mol Life Sci. 2019;76(3):473–493. https://doi.org/10.1007/s00018-018-2943-4.
13. Sommer F., Anderson J.M., Bharti R., Raes J., Rosenstiel P. The resilience of the intestinal microbiota influences health and disease. Nat Rev Microbiol. 2017;15(10):630–638. https://doi.org/10.1038/nrmicro.2017.58.
14. Baj A., Moro E., Bistoletti M., Orlandi V., Crema F., Giaroni C. Glutamatergic Signaling Along The Microbiota-Gut-Brain Axis. Int J Mol Sci. 2019;20(6):1482. https://doi.org/10.3390/ijms20061482.
15. Luo M., Zhuang X., Tian Z., Xiong L. Alterations in short-chain fatty acids and serotonin in irritable bowel syndrome: a systematic review and meta-analysis. BMC Gastroenterol. 2021;21(1):14. https://doi.org/10.1186/s12876-020-01577-5.
16. Cremon C., Carini G., Wang B., Vasina V., Cogliandro R.F., De Giorgio R. et al. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol. 2011;106(7):1290–1298. https://doi.org/10.1038/ajg.2011.86.
17. Aggarwal S., Ahuja V., Paul J. Dysregulation of GABAergic Signalling Contributes in the Pathogenesis of Diarrhea-predominant Irritable Bowel Syndrome. J Neurogastroenterol Motil. 2018;24(3):422–430. https://doi.org/10.5056/jnm17100.
18. Farzaei M.H., Bahramsoltani R., Abdollahi M., Rahimi R. The Role of Visceral Hypersensitivity in Irritable Bowel Syndrome: Pharmacological Targets and Novel Treatments. J Neurogastroenterol Motil. 2016;22(4):558–574. https://doi.org/10.5056/jnm16001.
19. Gros M., Gros B., Mesonero J.E., Latorre E. Neurotransmitter Dysfunction in Irritable Bowel Syndrome: Emerging Approaches for Management. J Clin Med. 2021;10(15):3429. https://doi.org/10.3390/jcm10153429.
20. Annaházi A., Róka R., Rosztóczy A., Wittmann T. Role of antispasmodics in the treatment of irritable bowel syndrome. World J Gastroenterol. 2014;20(20):6031–6043. https://doi.org/10.3748/wjg.v20.i20.6031.
21. Ruepert L., Quartero A.O., de Wit N.J., van der Heijden G.J., Rubin G., Muris J.W. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011;(8):CD003460. https://doi.org/10.1002/14651858.CD003460.pub3.
22. Ivashkin V.T., Maev I.V., Shelygin Yu.A., Baranskaya E.K., Belous S.S., Belousova E.A. et al. Diagnosis and treatment of irritable bowel syndrome: clinical recommendations of the Russian Gastroenterological Association and Association of Coloproctologists of Russia. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(5):74–95. (In Russ.) https://doi.org/10.22416/1382-4376-2021-31-5-74-95.
23. Poynard T., Regimbeau C., Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2001;15(3):355–261. https://doi.org/10.1046/j.1365-2036.2001.00937.x.
24. Christen M.M.O., Tassignon J.P. Pinaverium bromide: A calcium channel blocker acting selectively on the gastrointestinal tract. Drug Dev Res. 1989;(18):101–112. https://doi.org/10.1002/ddr.430180202.
25. López-Alvarenga J.C., Sobrino-Cossío S., Remes-Troche J.M., Chiu-Ugalde J., Vargas-Romero J.A., Schmulson M. Polar vectors as a method for evaluating the effectiveness of irritable bowel syndrome treatments: an analysis with pinaverium bromide 100mg plus simethicone 300mg po bid. Rev Gastroenterol Mex. 2013;78(1):21–27. https://doi.org/10.1016/j.rgmx.2012.10.003.
26. Salvioli B. Trimebutine: a state-of-the-art review. Minerva Gastroenterol Dietol. 2019;65(3):229–238. https://doi.org/10.23736/S1121-421X.19.02567-4.
27. Martínez-Vázquez M.A., Vázquez-Elizondo G., González-González J.A., Gutiérrez-Udave R., Maldonado-Garza H.J., Bosques-Padilla F.J. Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis. Rev Gastroenterol Mex. 2012;77(2):82–90. https://doi.org/10.1016/j.rgmx.2012.04.002.
28. Den Hertog A., Van den Akker J. Modification of alpha 1-receptor-operated channels by mebeverine in smooth muscle cells of guinea-pig taenia caeci. Eur J Pharmacol. 1987;138(3):367–374. https://doi.org/10.1016/0014-2999(87)90475-4.
29. Greenslade F.C., Scott C.K., Newquist K.L., Krider K.M., Chasin M. Heterogeneity of biochemical actions among vasodilators. J Pharm Sci. 1982;71(1):94–100. https://doi.org/10.1002/jps.2600710123.
30. Rosenzweig O., Lavy E., Gati I., Kohen R., Friedman M. Development and in vitro characterization of floating sustained-release drug delivery systems of polyphenols. Drug Deliv. 2013;20(3-4):180–189. https://doi.org/10.3109/10717544.2013.801532.
31. El Nabarawi M.A., Teaima M.H., Abd El-Monem R.A., El Nabarawy N.A., Gaber D.A. Formulation, release characteristics, and bioavailability study of gastroretentive floating matrix tablet and floating raft system of Mebeverine HCl. Drug Des Devel Ther. 2017;11:1081–1093. https://doi.org/10.2147/DDDT.S131936.
32. Chassagne P., Ducrotte P., Garnier P., Mathiex-Fortunet H. Tolerance and Long-Term Efficacy of Polyethylene Glycol 4000 (Forlax®) Compared to Lactulose in Elderly Patients with Chronic Constipation. J Nutr Health Aging. 2017;21(4):429–439. https://doi.org/10.1007/s12603-016-0762-6.
33. Evans P.R., Bak Y.T., Kellow J.E. Mebeverine alters small bowel motility in irritable bowel syndrome. Aliment Pharmacol Ther. 1996;10(5):787–793. https://doi.org/10.1046/j.1365-2036.1996.61203000.x.
34. Van Outryve M., Mayeur S., Meeus M.A., Rosillon D., Hendrickx B., Ceuppens M. A double-blind crossover comparison study of the safety and efficacy of mebeverine with mebeverine sustained release in the treatment of irritable bowel syndrome. J Clin Pharm Ther. 1995;20(5):277–282. https://doi.org/10.1111/j.1365-2710.1995.tb00663.x.
35. Lu C.L., Chen C.Y., Chang F.Y., Chang S.S., Kang L.J., Lu R.H., Lee S.D. Effect of a calcium channel blocker and antispasmodic in diarrhoea-predominant irritable bowel syndrome. J Gastroenterol Hepatol. 2000;15(8):925–930. https://doi.org/10.1046/j.1440-1746.2000.02230.x.
36. Lee K.J., Kim N.Y., Kwon J.K., Huh K.C., Lee O.Y., Lee J.S. et al. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine. Neurogastroenterol Motil. 2011;23(12):1098–1104. https://doi.org/10.1111/j.1365-2982.2011.01771.x.
37. Hou X., Chen S., Zhang Y., Sha W., Yu X., Elsawah H. et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBSQuality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014;34(11):783–793. https://doi.org/10.1007/s40261-014-0233-y.
38. Kennedy T., Jones R., Darnley S., Seed P., Wessely S., Chalder T. Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial. BMJ. 2005;331(7514):435. https://doi.org/10.1136/bmj.38545.505764.06.
39. Daniluk J., Malecka-Wojciesko E., Skrzydlo-Radomanska B., Rydzewska G. The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome-A Systematic Review. J Clin Med. 2022;11(4):1044. https://doi.org/10.3390/jcm11041044.
Review
For citations:
Khalaidzheva KN, Drozdov VN, Shikh EV, Serebrova SY. The place of antispasmodic drugs in modern therapy of irritable bowel syndrome. Meditsinskiy sovet = Medical Council. 2023;(8):189-195. (In Russ.) https://doi.org/10.21518/ms2023-127
Views:
360
Email this article 